For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
Dr. Courtney Coschi was recognized with the Elizabeth Eisenhauer Early Drug Development Young Investigator Award at the CCTG Spring Meeting. The award is presented to a new investigator who has worked at the CCTG Central Office, IND projects, or has contributed significantly to the conduct of an IND trial at a member centre.
Congrats to the MA39 clinical trials team at Tom Baker Cancer Centre in Calgary for receiving the ,Phase III Team Award for CCTG-Led Trials at a ceremony recently held at the Annual Spring Meeting in Toronto. The team awards are presented to trial teams from member centres for performance in trial accrual, local activation timelines, compliance metrics and team performance
Congratulations to the PR19 Team from the Odette Cancer Centre at Sunnybrook for being recognized with the Phase III Team Award for CCTG-Led Trials.
CCTG is very pleased to present the Joseph Pater Founder’s Award for Excellence in Clinical Trials Research to Dr. Jolie Ringash, a radiation oncologist at the University of Toronto. The award is presented yearly at the Spring Meeting to a clinical trials research investigator whose leadership and body of work has contributed to significant advances in the understanding, diagnosis, treatment, cure, and prevention of cancer.
CCTG former Directors joint statement regarding US requirements for identity proofing and multi-factor authentication
Congratulations to Dr. Ali Hosni Abdalaty from Princess Margaret Cancer Centre (UHN) for his Ralph Meyer Phase III Program Young Investigator Award received at the CCTG Spring Meeting.
CCTG IND243: A Phase II Study of RP-6306 in Patients with Advanced Cancer has been centrally activated.
This study is being done to answer the following questions:
New this year at the CCTG Spring Meeting is an open workshop and education session on engaging patient representatives in CCTG clinical trials. This accredited workshop takes place on Friday 28 at 10:30 in the Wren room at the Chelsea Hotel.
Participants are invited to discuss and assess the Investigator and Patient perspective in patient-centred clinical trials. There will be an exploration of the CCTG Patient Engagement Model and an assessment of the clinical trial lifecycle identifying touch points to engage patients.
